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Abstract: Antiretroviral therapy (ART) has significantly improved life expectancy of infected subjects,
generating a new epidemiological setting of people aging withHuman Immunodeficiency Virus
(HIV). People living with HIV (PLWH), having longer life expectancy, now face several age-related
conditions as well as side effects of long-term exposure of ART. Chronic kidney disease (CKD) is a
common comorbidity in this population. CKD is a relentlessly progressive disease that may evolve
toward end-stage renal disease (ESRD) and significantly affect quality of life and risk of death. Herein,
we review current understanding of renal involvement in PLWH, mechanisms and risk factors for
CKD as well as strategies for early recognition of renal dysfunction and best care of CKD.
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1. Introduction
Despite epidemiological data reporting a reduction of new cases of HIV infection, its prevalence
tends to augment globally because effective antiretroviral therapy (ART) has substantially increased
survival of people living with HIV (PLWH), generating a new epidemiological setting of individuals
aging with HIV [1].
Nowadays, life expectancy of highly educated PLWH treated chronically with combined ART
has reached that of the uninfected counterpart [2]. The aging PLWH are therefore at risk for several
age-related diseases including chronic kidney disease (CKD) [3]. Besides aging, several risk factors such
as viral infection itself, ART, HIV-related comorbidities (e.g., diabetes mellitus, cardiovascular disease),
coinfection (Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), tuberculosis) and polypharmacy impact
significantly on the development of kidney disease in this vulnerable population.
CKD is a relentlessly progressive disease that may evolve toward end-stage renal disease (ESRD).
It contributes to poor quality of life and increases mortality of all affected subjects because it is
associated with increased risk of cardiovascular disease, dyslipidemia, cognitive decline and bone
disorders—comorbidities commonly found in PLWH, irrespective of their renal function [4]. Hence,
superimposition of renal impairment on a complex disease such as HIV infection tends to increase
the burden of comorbidities and, theoretically, predicts a worse outcome in this population. The best
strategy to counteract the risk of CKD is based on prevention and early recognition of renal dysfunction
as well as early initiation of ART in order to prevent long-lasting viral replication, which in turn
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is responsible for potential kidney damage [5]. The aim of this review is to provide a descriptive
overview of the current understanding of CKD in the setting of HIV infection, focusing on prevalence,
presentation, pathogenesis and treatment. Description of collateral issues such as comorbidities,
coinfection and polypharmacy in PLWH who experienced CKD is out of the scope of this review.
2. Epidemiology of CKD in the Setting of HIV Infection
The measure of incidence and prevalence of CKD in the setting of HIV infection varies across
geographic areas with large differences also within the same continent. Variability depends on
a series of multiple factors such as methods to evaluate renal function, CKD definition, genetic
heterogeneity, prevention program, access to health care system and initiation of combined ART.
The first obstacle to overcome is the correct assessment of renal function since none of the methods used
to estimated glomerular filtration rate (eGFR) have been validated in PLWH. The most widely used
serum creatinine-based GFR estimating equations tend to be inaccurate in PLWH [6]. The major pitfall
is the measurement of serum creatinine since it does not reflect true renal function in individuals with
loss of lean body mass and malnutrition. Even cystatin C, an alternative marker of kidney function
not-related to lean muscle mass, needs further studies before to be used in this population because
it is influenced by HIV replication [7]. In addition, as in non-infected patients, it is unclear whether
age-related decline in GFR reflects or not a physiologic process in this subset of population.
Nuclear medicine method using 99mTc DTPA plasma clearance is the gold standard for GFR
assessment, but it is impractical in resource-limited countries. In these settings, Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) [8]—or Cockcroft−Gault (CG) [9]—based eGFRs result in the
most practical and economical methods to asses renal function.
The estimated prevalence of CKD in HIV population—measured using CKD-EPI
equation [8]—ranges from 2.5 % in Europe to 7.4% in North America [10]. If we consider that
36.9 million of people are currently living with HIV worldwide [1], CKD represents a challenging
problem with enormous implications for the national health care systems, probably not destined to be
managed effectively in the next years given that the prevalence of CKD is expected to increase in this
population [10]. PLWH have a slightly higher risk of developing CKD than HIV-uninfected subjects,
but once CKD has commenced, the likelihood of developing ESRD is 2- to 20-fold greater compared to
the uninfected counterpart [11,12]. The increased susceptibility is given by the combination of both
traditional and HIV-specific risk factors for kidney disease. The first ones, commonly encountered
in general population, include age, hypertension and diabetes [13]. The second are HIV replication,
AIDS status, hepatitis B and C coinfection, low CD4 nadir, lipodystrophy and ART [10,14–16]. In a
recent paper, Althoff et al. [17] elegantly estimated the population attributable fractions of preventable
or modifiable HIV-related (CD4+ T-cell count and viral load) and traditional risk factors for several
conditions including ESRD. The findings of this study showed that a substantial proportion of cases
of ESRD could be prevented with interventions on traditional risk factors including hypertension,
hypercholesterolemia, diabetes and smoking cessation.
Epidemiological studies have revealed that patients of African descent have an 18 to 50% higher
risk of developing HIV-related ESRD compared to whites [16,18,19]. This racial disparity is explained
principally by a severe disease with rapid progression to renal insufficiency in people of African
ancestry [16]. However, the risk of renal disease is not the same in all region of the African continent.
Notably, West Africa has the highest prevalence of kidney disease [10]: 14.6% in studies using MDRD
equation [20] and 9.2% in studies using CKD-EPI equation [8]. This unique susceptibility to developing
renal disease is principally due to genetic factors. Techniques that examined ancestry informative
markers have revealed that black patients, especially those living in West Africa and South Africa,
carry certain polymorphisms that are linked with an aggressive course of HIV-associated nephropathy.
In the last decade, risk alleles G1 and G2 of APO1, a gene sited on chromosome 22, have been strongly
associated with the development of the most severe form of HIV-associated glomerulonephrites such as
focal segmental glomerulosclerosis (FSGS) and HIV-associated nephropathy (HIVAN) [21,22]. Because
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up to 20–30% of patients of African origin have no APOL1 risk alleles, other variables may contribute to
the profile risk in developing HIV-related nephropathy [23]. Among them, confounding environmental
factors such as inadequate access to health care services and tendency of some national health policies
to start ARTs at defined CD4 T-cell count cutoffs [24] need to be strongly considered because they may
impact on the increased risk of CKD.
3. HIV Involvement in Kidney Disease
HIV infection is a chronic life-long illness which determines kidney damage essentially through
a direct and indirect mechanism that may affect all structures of the nephron (Figure 1). The first is
related to the cytopathic effect of the virus within the renal parenchymal cells resulting in the disruption
of the normal cell activity. The second is not directly related to the pathological interaction of the
virus with the infected cells, but relies on pseudopathological response of the immune system to HIV
infections (e.g., formation of immune complexes depositing in the kidneys, hyperimmune reaction to
HIV antigens), use of nephrotoxic drugs or other superimposed infections.
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Figure 1. A schematic view of the nephron (functional unit of the kidney) and potential HIV involvement.
Glomerular involvement has been described in HIV-associated nephropathy (HIVAN) (collapsing
glomerulopathy); focal segmental glomerulosclerosis (FSGS), not otherwise specified; immune complex
kidney disease. Tubulointerstitial involvement has been described as tubulointerstitial-dominant
HIV-related diseases or secondary to antiretroviral agents that may cause direct renal injury manifesting
with tubular dysfunction, acute interstitial nephritis and renal calculi. Vascular involvement called
vascular-dominant HIV-related diseases such as thrombotic microangiopathy (TMA) syndrome, porpora
thrombocytopenic (TTP), atypical hemolytic uremic syndrome (aHUS) have also been reported.
In order to offer a complet overview of renal disease in the context of chronic HIV infection,
in February 2018 the Kidney Disease Improving Global Outcomes (KDIGO) has classified the
nephropathies according to th tissue compartment involved [25] (Table 1). T e classification reports
also di betic and age-related lesions diagnosed in the setting of HIV.
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Table 1. Classification of HIV-related kidney disease and description of their treatment. Adapted from Swanepoel CR et al. “Kidney disease in the setting of HIV
infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference” Kidney Int. 2018;93(3):545–559 (see reference [25]).
HIV-Related Kidney Disease Directly Related to HIV Infection First-Line Treatment * Second-Line Treatment Adjunctive Therapies
I. Glomerular-dominant
a. Podocytopaties (e.g. HIVAN, FSGS) X ART Steroid, Cys A ACEi or ARB
b. Immune complex-mediated glomerular
disease (e.g. MPGN, IgAN) ART Steroid ACEi or ARB
II. Tubulointerstitial-dominant
a. Tubulointerstitial injury in the setting of classic
HIVAN X ART Steroid
b. Acute tubular injury or acute tubular necrosis
(associated with ART) Stop offending drug
c. Drug-induced tubulointerstitial nephritis
(other than ART) Stop offending drug Steroid
d. Direct renal parenchymal infection by
pathogens Treat the underling infection
e. Imuunologic dysfunction-related
tubulointerstitial inflammation
I. DILS
II. IRIS
I. ART
II. Treat the opportunistic
infection/ART
I. Steroid
II. Steroid
II. NSAID (risk of nephrotoxicity),
thalidomide, hydroxychloroquine,
anti-TNFalpha
f. Other tubulointerstitial inflammation in the
setting of HIV Treat underlining disease
III. Vascular-dominant
a. Thrombotic microangiopathy in the
setting of HIV
I. TTP
II. aHUS
I. X
II. X
I. ART, plasmapheresis
II. ART, Eculizumab I. Rituximab, bortezomib, Cys A I. Sterodi/antiplatelet agents
b. Arteriosclerosis X § ART/reduce risk factors foratherosclerosis
IV. Other, in the setting of HIV
a. Diabetic nephrolopathy Treat diabetes ACEi or ARB
b. Age-related nephrosclerosis ART ART/reduce risk factors foratherosclerosis
Anti TNF-α, anti-tumor necrosis factor-α; ART, antiretroviral therapy; Cys A, Cyclosporine A; DILS, diffuse infiltrative lymphocytosis syndrome, FSGS, focal segmental glomerulosclerosis;
HIVAN, HIV-associated nephropathy; IgAN, IgA nephropathy; IRIS, immune reconstitution inflammatory syndrome; MPGN, membranoproliferative glomerulonephritis; § Arteriosclerosis
is due partly to cytopathic effect of HIV and to the traditional and non-traditional risk factors for vasculopathy; * According to current guidelines, ART is administered in all patients with
the diagnosis of HIV infection regardless CD4 T-cell count. ART is indicated as the first-line approach when it is effective in the treatment of HIV-related kidney diseases.
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Given the wide variability of renal pathologies, renal biopsy remains the best way to diagnose
kidney disease accurately. To date, it is difficult to establish the likelihood of HIV as the etiologic factor
of the aforementioned nephropathy because the identification of HIV antigens and specific anti-HIV
antibodies within renal parenchyma is not practicable in the routine pathology laboratories. There
is a reasonable grade of certainty only in classical HIVAN and in podocytopathies in HIV-infected
newborns, whereas in all other cases causality is variable and is graded as high, medium and low.
According to the latest KDIGO classification, we describe histological, clinical features and
principles of treatment of the most common nephropathies encountered in HIV settings.
3.1. Glomerular-Dominant HIV-Related Diseases
HIVAN is a well-defined clinicopathologic entity manifesting as collapsing glomerulopathy
associated with a consistent tubulointerstitial disease. The collapsed glomerulus is accompanied by
dramatic hypertrophy and hyperplasia of the overlying glomerular epithelial cells, which tend to
fill the urinary space [26]. IgM, C3 and C1q are generally detected in the collapsed segments and
mesangial areas.
Tubules are focally enlarged (microcysts) and contain glass cast; often there is tubular atrophy,
interstitial fibrosis and inflammation. At electron microscopy evaluation, the collapsed tuft is
characterized by wrinkling of the glomerular basement membrane and hypertrophy of the overlying
podocytes. Foot process effacement is observed both in collapsed and non-collapsed glomerulus.
Classical HIVAN is strongly associated with APOL1 risk allele [27], South Africans [28] and low CD4+
T-cell count [29]. It manifests during acute HIV infection or AIDS-defining illness. Kidneys appear
echogenic and often are enlarged on ultrasound imaging. Main clinical presentation is nephrotic
proteinuria and rapid progression to ESRD. The mainstay of treatment for an ART-naïve patient is
initiating antiretroviral drugs and avoiding potentially nephrotoxic agents. More importantly, ART
may protect infected children from HIVAN, a disease associated with a tragic outcome in areas where
there is a lack of facilities for renal replacement therapy (RRT) [30].
In the pre-ART era, several therapies were attempted to treat HIV-associated nephropathy.
Observational studies showed that corticosteroid, the first-line therapy for non-HIV-related focal
segmental glomerulosclerosis, was beneficial in the treatment of HIVAN [31–34].
In a retrospective cohort of 21 patients with biopsy-proven HIVAN, corticosteroid was administered
at dosage of 60 mg for one month, followed by tapering over several months. Treated patients had a
significantly slower progression of renal failure and improvement of proteinuria without an increased
risk of infection, but relapse of proteinuria was common after reduction or steroid withdrawal [35].
Infectious Diseases Society of America (IDSA) guidelines [36] suggests treating HIVAN promptly with
ART to reduce the risk of progression to ESRD. Angiotensin-converting-enzyme (ACE) inhibitors or
angiotensin II receptor blockers should be used in the presence of stable renal function, and dose
should be adjusted carefully in order to prevent hyperkalemia.
The strategy is to administer corticosteroid therapy in patients with progressive worsening of
renal function despite optimal therapy with ART and angiotensin inhibition after exclusion of recent or
subclinical chronic infections such as tuberculosis or viral hepatitis. In case of relapse, a further cycle of
steroid is used in order to attain remission of proteinuria. Physicians should keep in mind that systemic
corticosteroid may have notable infective complications (e.g., reactivation of herpes virus infections,
tuberculosis, progression of Kaposi sarcoma and mucocutaneous candidiasis) as well as metabolic side
effects (i.e., hyperglycemia, hypertension, osteoporosis and gastrointestinal ulceration) [37]. Therefore,
a careful balance of the short-and long-term risks and potential benefits of steroid therapy should be
undertaken before its use.
Focal Segmental Glomerulosclerosis (FSGS), not otherwise specified (NOS), in the setting of
HIV, is a virus-mediated attenuated form of FSGS. The main lesion is segmental sclerosis/segmental
obliteration of capillary loops with matrix increase (with or without hyalinosis) within the glomerulus
and adherence of capillary tuft to Bowman’s capsule [26]. Tubulointerstitial disease and the grade
J. Clin. Med. 2019, 8, 1254 6 of 19
of podocyte effacement are generally less prominent than HIVAN. Different to HIVAN, it is more
frequent in Caucasians than in African-Americans [27,38]. This variant is usually encountered in
patients treated with ART with an undetectable viral load.
It is unclear whether FSGS represents an identity different from HIVAN or lies in the same
spectrum; it may be an attenuated histopathological pattern of HIVAN in patients treated with
ART [27,38]. However, to confirm a presumed causality with HIV, other causes of FSGF should
be excluded. Differential diagnosis of FSGS includes primary (idiopathic) FSGS, virus-associated
forms (e.g., parvovirus B19 infection, SV40 infection, acute Cytomegalovirus (CMV) infection), drug
induced-forms (e.g., interferon therapy, pamidronate toxicity) and forms mediated by adaptive
structural-functional responses (e.g., hypertensive arterionephrosclerosis, diabetes, obesity). Treatment
strategy is similar to that of HIVAN.
Immune complex kidney disease is a group of glomerulonephritis that includes IgA
nephropathy (IgAN), lupus-like nephritis, membranous nephropathy and membranoproliferative
glomerulonephritis. Technically, it is difficult to establish a clear causal link between these
glomerulonephrites and viral infection; thus, the diagnosis of immune complex kidney disease
in the setting of HIV remains plausible only when other secondary causes have been excluded. Clinical
presentation is variable and depends on the location and extension of glomerular immune deposits.
Generally, urinary sediment is active with dysmorphic red cells, there is a variable degree of proteinuria
and the serum creatinine may be normal or elevated. Prognosis is better than HIVAN.
All glomerulonephritis but IgAN seem benefit from administration of ART [39]. If ART does not
modify the course of glomerulonephritis ACE-Is or ARBs should be considered in relation to the grade
of renal dysfunction. Immunosuppressive agents including steroids can be used in case of disease
progression although this recommendation is not evidence-based as it derives from single clinical case
reports and case series [40].
3.2. Tubulointerstitial-Dominant HIV-Related Diseases
Tubulointerstitial disease in the setting of HIV is due to classical HIVAN, drug toxicity or infections.
Two forms are related to abnormal response of immune system to HIV: (i) diffuse infiltrative
lymphocytosis syndrome (DILS) and (ii) immune reconstitution inflammatory syndrome (IRIS). The first
is a hyperimmune reaction against HIV antigens. The second is an inflammatory syndrome directed
against infectious antigens disseminated in the renal parenchyma, elicited by the recovery of immune
system after starting of ART [41]. Both diseases are rare and are characterized by prominent interstitial
CD8 T-cell infiltrates.
Treatment of tubulointerstitial disease in the setting of HIVAN is described above, whereas
management of drug nephrotoxicity and infectious disease is targeted to remove the offending agent
and to treat the underlying infection, respectively.
First-line treatment of DILS is ART. Six to eight weeks of steroid are used to resolve severe organ
dysfunction and allow rapid recovery of their function [42].
Management of IRIS is complex because phytopathology of the disorder is unknown. In the
majority of cases, ART is continued and opportunistic infection is treated accordingly. Steroids may be
needed for patients who develop severe kidney disease [37].
3.3. Vascular-Dominant HIV-Related Diseases
Vascular disease is the result of both direct and indirect effect of HIV infection on vessels. Although
the virus is able to infect and dysregulate endothelial cells, multiple factors such as ART, HIV-associated
comorbidities (i.e., dyslipidemia, chronic inflammations), traditional risk factors for arteriosclerosis
(i.e., age, smoking, alcohol use) and nontraditional risk factors (i.e., hepatitis C, substance use or abuse)
affect the development of vasculopathy. PLWH are prone to experience progressive atherosclerosis that
involves pathological lipid metabolism and inappropriate activation of innate and adaptive immune
systems in the arterial wall [43]. The process is so early that ART-naïve children without a significant
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burden or duration of risk factors for coronary heart disease have an increased carotid intima–media
thickness (marker of atherosclerosis) compared to children without HIV infection [44].
Thrombotic microangiopathy (TMA) syndrome is a life-threating manifestation of HIV infection.
The disease affects small blood vessels, and endothelial cell injury appears to be the primary event.
It manifests with thrombocytopenia, microangiopathic hemolytic anemia, microvascular thrombosis
and multisystem organ dysfunction [45]. The spectrum of renal injury ranges from mild to severe,
sometimes requiring RRT [40]. The first step in the diagnosis of HIV-related TMA is rolling out
infections and malignancies. These are common in patients with HIV/AIDS and can be themselves
causes of purpura thrombocytopenic (TTP) or precipitating factors for atypical hemolytic uremic
syndrome (aHUS). Treatment of TTP driven by HIV is based on the institution of ART, plasma exchange,
and immune suppression (second-line therapy) [46]. Anti-C5 monoclonal antibody (eculizumab) is
instead effective for the treatment of aHUS [47].
3.4. Other, in the Setting of HIV Infection
Diabetic nephropathy and arterionephrosclerosis may develop in PLWH given their multiple risk
factors. HIV infection is associated with a four-fold increased risk of type 2 diabetes [48] and a poor
glycemic control [49] compared to the uninfected counterpart. In a murine model, the expression of
HIV-1 genes aggravates the progression of diabetic nephropathy, probably due to an upregulation
of inflammatory citokines [50]. Arterionephrosclerosis is secondary to hypertension. Both diabetic
nephropathy and arterionephrosclerosis manifest with proteinuria that may progress to nephrotic
range in patients with long-term diabetes and severe hypertension.
Histological evaluation of kidney biopsy in diabetic nephropathy and arterionephrosclerosis
shows both typical lesions of the underlying disease (e.g., Kimmelstein–Wilson nodules in diabetics
and arterial wall medial thickening with arteriolar hyaline deposits in arterionephroslerosis) and
sclerosis involving the perihilar region of the glomerulus. This latter histological pattern is compatible
with a diagnosis of adaptive FSGS resulting from an excessive workload of the remaining nephrons.
Treatment is directed toward the underlying cause.
4. Nephrotoxicity of ART
WHO guidelines recommend a combination of three drugs to suppress HIV replication and
prevent the development of drug-resistance strains. Therapy is generally based on two nucleos(t)ide
reverse transcriptase inhibitors (NRTIs) (the “backbone” of ART) and a third agent from another class.
The advent of ART has dramatically changed outcome of HIV+ patients in the last two decades
reducing mortality and risk of progression to AIDS, even though important adverse side effects
including nephrotoxicity arose with its use. Direct renal injury occurs with tubular dysfunction, acute
interstitial nephritis and renal calculi. Indirect mechanisms of injury are due to medication dosing errors,
drug–drug interactions, ART-induced rhabdomyolysis, lactic acidosis and metabolic complications.
Here we describe principal direct and indirect renal toxicity mediated by current
antiretroviral drugs.
5. Direct Mechanism
5.1. Tenofovir
Tenofovir disoproxil fumarate (TDF) is a “preferred” nucleotide reverse transcriptase inhibitor
(NRTI) widely used as part of antiretroviral therapy. Tenofovir is eliminated by renal elimination;
dose-interval adjustments are mandatory in patients with renal impairment, even though its use is not
recommended when GFR is less than 60 mL/min [36]. Nephrotoxicity of TDF has been extensively
debated during the last decade because studies provided controversial results. Whereas clinical trial [51]
and post-marketing report [52] did not report significant nephrotoxicity, observational studies [53–57]
showed a concerning decline of renal function in a minority of patients [58]. Likely, the exclusion from
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trials of patients with CKD and the more frequent use of a less sensitive serum creatinine level than
eGFR accounted for these differences. To shed light on this issue, a meta-analysis that included 10,889
participants showed that TDF-containing ART regimens were associated with a modest but significant
loss of kidney function and a higher risk of acute renal injury compared to controls [59].
TDF causes kidney damage in 1–5% [52,60–62] of the cases, principally in patients with pre-existing
renal disease, risk factors for CKD, concomitant use of potentially nephrotoxic agents, a low CD4 T-cell
count and viral hepatitis B and/or C [63–66]. The risk of TDF-nephrotoxicity seems to increase with the
concomitant use of other antiretroviral regimens; in particular, ritonavir-boosted protease inhibitor
(PI/r) induces a greater decline in GFR than a non-NRTI agent, by increasing TDF exposure [57,67].
The mechanism underlying kidney damage is partially known, but it is likely related—as
all NRTIs—to mitochondrial toxicity [68]. The main site of toxicity is the proximal tubule [69].
In a large cohort of 1202 patients, TDF increased the risk of proximal renal tubulopathy of
about 3.3 fields compared with tenofovir-naïve patients [70]. Tubular dysfunction manifests with
phosphaturia, hypophosphatemia and in an increase in serum alkaline phosphatase [71]. A complete
Fanconi syndrome, characterized by a variable grade of glycosuria without diabetes, aminoaciduria,
phosphaturia and renal tubular acidosis is instead uncommon in these patients. The most severe
consequence of the loss of phosphate is an increased bone turnover manifesting with osteomalacia,
a disease characterized by impaired mineralization in regenerating bone and pseudo-fracture around
multiple joints [72].
Proximal tubular dysfunction is often overlooked because laboratory examinations show mild
alterations, and initial presentation occurs without changes in kidney function; therefore, the diagnosis
is often tardive and made during the worsening of renal function. TDF is able to induce distal tubular
toxicity manifesting as nephrogenic diabetes insipidus [73] and distal renal tubular acidosis [74].
Compared to proximal renal tubular acidosis, determined by a defect in the ability to reabsorb
bicarbonate, distal tubular acidosis is characterized by impairment in net acid secretion.
Tubular toxicity can lead to both a rapid and gradual reduction of renal function [75] which
generally occurs during the first six months from its administration [67].
Acute renal failure has been reported between <1 and 2.2% [52,76,77]. There are conflicting data
about reversibility of kidney injury after an episode of acute kidney insufficiency (AKI). It seems that
renal dysfunction is only in part reversible [78–80]. A study conducted in 24 PLWH males, who stopped
TDF for worsening of renal function, showed that renal injury was fully reversible only in 42% of
subjects. Recovery of renal function occurred until the fifth month but the most improvement was
documented during the first month after TDF withdrawal. The greatest GFR improvement was seen in
patients with a rapid onset of AKI and a combining therapy with a PI/r. This suggests that a more
rapid and, thus a more clinically recognizable, worsening of renal function is more likely to be fully
reversible. Consequently, it is possible that the prolonged use of TDF causes an irreversible chronic
tubule-interstitial fibrosis preventing the full recovery of the injury. However, the overall rate of
discontinuation of TDF due to adverse renal events was lower than 2% [54,77,81].
Given the large use of TDF in ART regimen, all patients should be periodically evaluated
(biannually) for tubular toxicity with analysis of serum phosphate level, and urine protein and glucose
content [82]. This is particularly valid for patients with a combining therapy with ritonavir-boosted
PIs. Data on use of TDF in patients with CKD are scarce and limited at one study in which the
dose of the drug was inappropriately high for the grade of renal dysfunction. However, two of
them (15.3%) experienced a concerning increment of serum creatinine level [77]. Dosage of beta
2-microglobulin, a marker of tubule damage, has been used to identify early patients who are at
increased risk of kidney disease [83]. Nishijima et al. [84] documented for the first time that the
measurement of beta 2-microglobulin within 180 days after initiation of TDF predicts the development
of TDF-related nephropathy.
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5.2. Tenofovir Alafenamide
Tenofovir alafenamide (TAF) is a novel prodrug of TDF recently approved for the first-line
treatment of HIV+ patients. It is approved by Food and Drug Administration (FDA) as part of
co-formulation and thus it is not available as single agent for the treatment of HIV infection. In the
USA and Europe, TAF is usable as a stand-alone agent for treatment of chronic HBV infections. Studies
comparing the pharmacokinetic properties of TAF and TDF have shown that TAF is able to reach a
higher intracellular level in peripheral blood mononuclear cells than TDF, despite a lower concentration
of the drug (about 90%) in the blood plasma [85–87]. Moreover, TAF has minimal mitochondrial
toxicity compared to TDF in vivo studies [88]. Based on these findings, TAF-containing regimen leads
to a more favorable renal and bone safety profile compared to TDF-containing regimen [89]. Two cases
of TAF induced nephrotoxicity have been published to date, but it is difficult to ascribe the renal injury
to TAF administration because more potential contributors were preexistent in those patients [90,91].
Further data are also necessary to evaluate the potential risk of TAF to induce Fanconi syndrome [92].
5.3. Protease Inhibitors
The protease inhibitors indinavir (IDV), lopinavir (LPV) and atazanavir (ATZ) have all been
associated with renal stone formation [93]. IDV, an old drug responsible for significant formation of
crystallization and stone formation in the urinary tract, is no longer used as antiretroviral therapy
because has been replaced by newer drugs with a better side-effect profile [94].
Atazanavir is generally well tolerated and widely used with a boosting dose of ritonavir. Atazanavir
has been associated with numerous case of crystalluria and nephrolithiasis [95]. Hamada et al. [96]
found that ATZ had a hazard ratio of nephrolithiasis of 10.44 compared with other PI. ATZ withdrawal
after the diagnosis of nephrolithiasis avoided new renal stone formation whereas continuum of the
antiretroviral drug exposed the patients to recurrence of the disease [96]. Risk factors for calculi are
dehydration, alkaline urine and a history of nephrolithiasis. Stones are radiolucent and are therefore
not evident with abdomen X-rays [97].
5.4. Integrase Inhibitor
Raltegravir (RAL) and dolutegravir (DTG) are two antiretroviral drugs in the class of integrase
inhibitors. According to recent WHO guidelines RAL and DTG are an alternative option to efavirenz
for first-line ART [98]. Their renal effect is not insignificant as both drugs tend to increase serum
creatinine concentration [99].
Metabolism of RAL occurs both in kidney and liver, but recommended dose remained unchanged
in patients with CKD. Serum creatinine increase during the first 3–4 weeks of treatment without a
tendency towards progression; a mean estimated creatinine clearance reduction of 5.4 mL/min was
recorded after one year from its administration [100]. RAL causes an increase in serum creatinine
without affecting tubular handling of creatinine. In fact, contrary to previous thinking, RAL does not
block creatinine secretion through the inhibition of organic cation transporter 2 (OCT2) as DTG [99].
The mechanism underlying renal dysfunction is unknown and there are no data about the reversibility
of the phenomenon to date. The decrease of cystatin C-based estimated GFR [101] may suggest a
potential detrimental effect of RAL on renal blood flow or interstitial compartment.
DTG does not need dose adjustment in CKD because it is excreted in urine for less than 1%.
DTG augments plasma creatinine concentration thought inhibition of OCT2, a co-transporter of the
basolateral side of proximal tubule cells responsible for urinary excretion of creatinine and drugs such
as metformin and ranitidine. In this way, the unsecreted creatinine tends to increase in blood without
an effective reduction of GFR due to drug-induced nephrotoxicity [102]. Similar to RAL, increase
in serum creatinine level is not-progressive and occurs within the first four weeks of therapy [103].
The decline of CrCl is greater compared to RAL, 16.5 vs 5.4 mL/min at one year [100].
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5.5. Cobicistat
The metabolism of cobicistat (COBI) is predominantly hepatic and dose adjustment is unnecessary
in renal impairment. COBI has no antiviral activity against HIV. It acts, through inhibition of CYP3A,
as a pharmaco-enhancer of atazanavir, darunavir or elvitegravir. This drug inhibits MATE1 (multidrug
and toxin extruder protein1) a transporter located on the apical side of the proximal tubule responsible
for the tubular excretion of creatinine. As a side effect, COBI increases serum creatinine levels and thus
reduces eGFR without affecting true GFR [104].
6. Indirect Mechanism of Nephrotoxicity
About 50% of antiretroviral agents need dose adjustment in CKD. Inadequate dosing is common
among CKD patients and it has been associated with treatment inefficacy, viral resistance and organ
toxicity [105]. As recommended by FDA, drug dosing in renal dysfunction is based on creatinine
clearance estimated by CG equations [9]. Unfortunately, this formula is inaccurate for extreme value
of body weight and age. As a result, sarcopenia, malnutrition and ethnic differences impair true
estimation of creatinine clearance and, thus, induce the physicians to make erroneous prescription of
drugs. In this context, nuclear medicine techniques or 24-hour creatinine clearance [106] (for example,
in low-income countries) may furnish valid support to dosing medications correctly.
Renal dysfunction can also result indirectly from drug interactions. The most common interactions
in HIV-infected CKD patients occur principally with calcium channel blockers and statins. Drugs such
as amlodipine, diltiazem, felodipine and nifedipine are metabolized by cytochrome P3A4, and as such
their concentrations increase with concomitant administration of PIs, COBI (cytochrome inhibitors)
and decrease with NNRTIs (cytochrome inducers).
Regarding statins, simvastatin and lovastatin, both metabolized via CYP3A4, and should be
avoided for the risk of severe myopathy and rhabdomyolysis. Fluvastatin, pitavastatin and pravastatin
are preferable for their low potential of interactions. Atorvastatin and rosuvastatin are potent reducers
of total LDL cholesterol, but their use is hindered by the moderate risk of drug-interactions and
development of proteinuria, respectively [107].
Skeletal muscle involvement in HIV infection varies from asymptomatic muscle enzyme elevation
to severe rhabdomyolysis. Zidovudine (ZDV) and abacavir may lead to myopathy, presumably through
impairment of mitochondrial function. Rhabdomyolysis-induced AKI is a rare event and only few
cases have been described in literature [108]. It occurs in patients with concomitant severe infection or
in the context of substance abuse [109].
Didanosine (ddI), stavudine (d4T) and less frequently ZDV have been implicated in the
pathogenesis of lactic acidosis. The mechanism underlying this condition is mediated by mitochondrial
toxicity. Renal involvement manifests with acute renal failure, primarily due to prerenal causes
(hypovolemia, reduced renal perfusion) [110].
ART determines a wide spectrum of metabolic alterations that may increase the occurrence of renal
disease. All antiretroviral agents and protease inhibitors in particular are associated with cardiovascular
disease that is mediated at least partly by dyslipidaemia [111]. Recently, the findings coming from a
prospective cohort of the D:A:D study showed that darunavir, similar to the first-generation protease
inhibitor, is associated with progressive increased risk of cardiovascular disease. Conversely, atazanavir
lacks cardiovascular side effects [112].
The prevalence of diabetes mellitus rises constantly among PLWH with ART and is four times
higher in infected patients with ART than in those uninfected [48]. Protease inhibitors and NRTIs are
known to impair glucose tolerance, as well as predispose to frank diabetes mellitus. An increased
rate of diabetic nephropathy has not been demonstrated but should be taken into account in case of
albuminuria or proteinuria.
In addition, some antiretroviral agents affect lipid profile and increase the risk of renal vascular
disease [113]. Drugs like NRTIs (i.e., ddI, d4T, ZDV) are well-known to induce hypertriglyceridemia,
whereas NNRTIs, mainly efavirenz, predisposed to hypertriglyceridemia and hypercholesterolemia.
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Abacavir instead increased the risk of cardiovascular diseases even in the absence of apparent lipid
disorders [114].
7. Emerging Therapy
Doravirine (DOR) and bictegravir (BIC) are two novel antiretroviral agents recently approved
by FDA for HIV treatment. Doravirine (DOR) is a recently approved NNRTI characterized by
unique resistance profile, lack of food restriction and drug–drug interaction with antacids. DOR is a
promising antiretroviral agent with the potential to become the first-line preferred regimen in naïve
patients [115]. It does not require dose adjustment in patients with renal impairment nor when eGFR
is less than 30 mL/min/1.73 m2 [116]. Bictegravir (BIC) is a newer INSTI acting without the need for
a pharmacologic booster such as COBI or ritonavir (RTV). It is available only in the coformulation
with TAF and emtricitabine (FTC). Since TAF an FTC need dose reduction in CKD this single-tablet
regimen is not recommended in patients with moderate or severe CKD. The armamentarium of ART is
expanding even with the use of biological therapies. Leronlimab (PRO 140) is a humanized antibody
on the horizon. Target of leronlimab is CCR5, a receptor required for HIV-1 to enter macrophages,
dendritic cells, and CD4 T-cells [117].
Regarding two-drug regimens, CKD patients with a suppressed viral load and no history of drug
resistance have the opportunity to receive more tolerated and simpler maintenance therapy with DTG
plus rilpivirine (RLP) compared to standard ART regimen [118]. More recently, the combination of
DTG plus lamivudine (3TC) has been shown to be effective in treatment-naïve individuals [119].
8. Treatment of CKD
Treatment of CKD is based on blockade of the renin-angiotensin-aldosterone system and risk factor
reduction. Diseases such as hypertension, diabetes, hyperuricemia, dyslipidemia and acidosis should
be treated efficiently to prevent progression of renal disease. For patients who live in high-income
countries and reach ESRD there are three options for treating uremia: hemodialysis, peritoneal dialysis
and kidney transplantation. Patients on dialysis with a suppressed VL have survival rates comparable
to dialysis patients without HIV infection, and choice of dialysis modality does not change outcomes.
In low-income area, peritoneal dialysis is an alternative RRT option for ESRD patients because it is
characterized by limited cost compared to HD. However, future studies are necessary to evaluate its
safety since a high rate of peritonitis has been found among PLWH [120,121]. Kidney transplantation
is the better option for HIV-infected individuals with ESRD requiring RRT [122]. Apart from a
high rate of graft rejection, outcome of kidney transplant recipients is now similar to the uninfected
counterpart [123].
In low-income countries as in Africa, treatment of CKD is hindered by limited numbers of
nephrologists, limited resources, poor access to RRT and a high prevalence of poverty [124]. Here,
there is no treatment of ESRD because dialysis is highly expansive and consumes a large proportion of
the health budget. For this reason, country such as South Africa, have rationalized access to RRT only
for patients who are suitable for transplantation [125]. Surprisingly, the prevalence of PLWN among
individuals presented for dialysis is low compared to the proportion of HIV-infected individuals in
the general population. This unexpected difference is due to the restrictive criteria of this program,
indeed patients with uncontrolled HIV replication have no access to RRT [125]. Based on these data,
early diagnosis and management of HIV would reduce the burden of health care cost associated
with treatment of CKD and increase the number of PLWH that can be considered for dialysis and
transplantation. In view of the advanced nature of presentation and lack of dialysis facilities, greater
efforts are necessary to prevent early CKD. Screening programs for early diagnosis of kidney disease
are needed at HIV detection as well as concurrent screening for diabetes and hypertension.
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9. Conclusions
HIV infection and CKD are two epidemic diseases with important social, clinical and economic
implications. The interplay between these two diseases represents an interesting intersection between
communicable and non-communicable diseases. Kidney disease and its associated risk factors are
frequently found among HIV-infected patients, irrespective of the improvements with the use of
ART, and it remains a cause of morbidity and mortality. The associated risk factors for kidney in this
population include black race, older age, hypertension, diabetes, low CD4 T-cell count, and high viral
load. The introduction of multi-drug combination therapy for the treatment of HIV has changed renal
and overall outcome of PLWH over the last two decades.
In the ART era, renal involvement is due principally to the toxic effects of ART and the multiple
comorbidities of PLWH, even though a potential cytopathic effect of the virus may be also expected
during ART with viral suppression [126]. Since the prevalence of HIV infection is high, nephrologists
and HIV specialists will more frequently face patients with a variable grade of renal insufficiency
and inevitably on RRT. The goal of their integrated multidisciplinary approach relies on close
monitoring of renal function, mitigating the adverse effects of polypharmacy and avoiding inappropriate
drug prescriptions.
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